Education
About Us
Working with TipRanks
Follow Us
Gri Bio, Inc. (GRI)
NASDAQ:GRI
GRI Stock Chart & Stats
$0.28
-$0.06(-7.48%)
At close: 4:00 PM EST
$0.28
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$2.10 - $311.35
Previous CloseN/A
Volume96.89K
Average Volume (3M)656.34K
Market Cap
$3.71M
Enterprise Value-$7.93M
Total Cash (Recent Filing)$8.23M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta2.37
Next Earnings
May 20, 2026EPS Estimate
-12.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding1,445,029
10 Day Avg. Volume42,927
30 Day Avg. Volume656,335
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-2.14
Enterprise Value/Revenue-0.27
Enterprise Value/Gross Profit1.98K
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$10.00Price Target Upside3471.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-48.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsBiomarker and lung-function signals from Phase 2a indicate target engagement and disease‑sparing activity, supporting advancement to larger, confirmatory trials.
Clinical SafetyAnalyst notes Phase 2a established a clean safety profile with no tolerability concerns observed at 12 weeks, which could increase prescriber confidence and uptake.
Market OpportunityHigh unmet need in idiopathic pulmonary fibrosis and an apparent safety advantage versus existing therapies could enable meaningful market share and use in combination regimens.
Bears Say
Clinical Trial RiskSmall size of the Phase 2a trial means the encouraging results carry significant uncertainty until confirmed in larger, well-powered studies.
Development RiskLong development and commercialization pathway creates elevated risk of clinical setbacks or regulatory hurdles that could delay or prevent market entry.
Financing RiskLimited cash runway before commercial revenues may require additional fundraising, creating dilution risk or timing pressure on clinical programs.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $2.10 and its highest was $311.35 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $3.71M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is May 20, 2026 which is in 72 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.08.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate is -12.88.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 1,445,029 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went up 2.764%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$10.00
▲(3471.43% Upside)
Technical Analysis
Ownership Overview
39.64%
Insiders
1.96% Mutual Funds
― Other Institutional Investors
57.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---